CLINICAL TRIAL SUMMARY

MDACC Study No:2011-0030 (clinicaltrials.gov NCT No: NCT01424982)
Title:PHASE II STUDY OF COMBINATION OF HYPER-CVAD AND PONATINIB IN PATIENTS WITH PHILADELPHIA (PH) CHROMOSOME POSITIVE AND/OR BCR-ABL POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)
Principal Investigator:Susan O'Brien
Treatment Agent:Adriamycin; Citrovorum; Cyclophosphamide; Cytarabine; Dexamethasone; G-CSF; Methotrexate; MESNA; Ponatinib; Prednisone; Solumedrol; Vincristine
Study Status:Closed
Study Description:The goal of this clinical research study is to learn if intensive chemotherapy
combined with ponatinib, followed by maintenance therapy, can help to control
ALL with the Ph chromosome and/or BCR-ABL. The safety of this treatment will
also be studied.

Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase II
Treatment Agents:Adriamycin
Citrovorum
Cyclophosphamide
Cytarabine
Dexamethasone
G-CSF
Methotrexate
MESNA
Ponatinib
Prednisone
Solumedrol
Vincristine
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:
Supported By:Ariad
Return Visit:
Home Care:


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Susan O'Brien
Dept:Leukemia
For Clinical Trial Enrollment:713-792-7543
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults